A Phase 1, Open-Label Study of the Safety, Pharmacokinetics and Pharmacodynamics of JNJ-64457107, an Agonistic Human Monoclonal Antibody Targeting CD40 in Patients With Advanced Stage Solid Tumors

Trial Profile

A Phase 1, Open-Label Study of the Safety, Pharmacokinetics and Pharmacodynamics of JNJ-64457107, an Agonistic Human Monoclonal Antibody Targeting CD40 in Patients With Advanced Stage Solid Tumors

Recruiting
Phase of Trial: Phase I

Latest Information Update: 11 Dec 2017

At a glance

  • Drugs ADC 1013 (Primary)
  • Indications Solid tumours
  • Focus Adverse reactions
  • Sponsors Janssen Research & Development
  • Most Recent Events

    • 06 Dec 2017 Planned End Date changed from 15 Dec 2019 to 1 Oct 2019.
    • 06 Dec 2017 Planned primary completion date changed from 7 Jan 2019 to 1 Jan 2019.
    • 25 Oct 2017 According to an Alligator Bioscience media release, this study is ongoing with approximately 50 patients recruited to date.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top